clinical trial · NCT05580042
Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare
TWi Biotechnology, Inc.·phase1·completed·n = 13
Granuloma AnnulareAC-1101
brief summary
Study AC-1101-GA-001 is an early phase open-label study with a 4-week treatment and 2-week follow-up period (without treatment) to assess the safety, tolerability, and efficacy of AC-1101 gel in patients with Granuloma Annulare.
started
Oct 3, 2022
primary completion
Nov 15, 2023
completion
Nov 15, 2023
last updated
Oct 15, 2024
official title
An Open-Label, Single Arm, Phase I Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol